Contact allergy to crisaborole in a paediatric patient with atopic dermatitis
Contact Dermatitis · 2023
DOI: 10.1111/cod.14389 ↗At a glance
Fallbericht in Contact Dermatitis, 2023. Written by Puneet Arora and 1 co-authors. Institution: Department of Dermatology, Park Nicollet Health Services, Minneapolis, Minnesota, USA. Major MEDLINE topics: Dermatitis, Atopic, Dermatitis, Allergic Contact. Cited 3 times so far (Crossref); 5 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Crisaborole (CAS No. 906673-24-3) is the active ingredient in a nonsteroidal topical ointment first approved in the United States to treat mild-to-moderate atopic dermatitis in 2016 for adults and children over 3 months of age (Eucrisa, crisaborole 2% cream; Pfizer, New York, NY). The product received marketing authorization in the EU in 2020, which was withdrawn shortly thereafter by the manufacturer (Staquis, Pfizer). Its mechanism of action is through downregulation of pro-inflammatory cytokines via phosphodiesterase-4 (PDE-4) inhibition. Given the paucity of alternatives to topical steroids, especially among paediatric patients, crisaborole has emerged as a popular therapeutic option in the United States.1 While the allergenic potential of topical corticosteroids2, 3 and calcineurin inhibitors4 is well documented, only one small case series of two patients with allergic contact dermatitis (ACD) to crisaborole has been previously reported.5 A 9-year-old female with a history of atopic dermatitis since infancy presented to our patch testing clinic with worsening pruritic, eczematous lesions over the past 2 years, particularly on her hands and lips. She had utilized numerous topical treatments including emollients, corticosteroids, tacrolimus and Eucrisa with only modest improvement in her dermatitis. She had previously discontinued Eucrisa due to lack of efficacy. She was patch tested to the North American Contact Dermatitis Group (NACDG) standard series in addition to history-driven supplemental series (SmartPractice, Phoenix, AZ) and select personal products, including Eucrisa (as-is). Patches were applied to unaffected skin on the patient's back using IQ Ultra chambers (Chemotechnique Diagnostics, Vellinge, Sweden) and removed after 48 h. At the 48-h reading, she was noted to have a mild (1+) reaction to Eucrisa. At the final (96-h) reading, her reaction to Eucrisa was still present along with additional positive reactions to bacitracin (20% pet), neomycin (20% pet), and hydroperoxides of limonene (0.3% pet; Figure 1). An additional confirmatory Eucrisa test was applied to the lateral upper arm at the 48-h reading, which again demonstrated a mild (1+) reaction after 48 h. Notably, the patient did not react to the following inactive ingredients in Eucrisa: butylated hydroxytoluene (BHT), paraffin, propylene glycol, and edetate calcium disodium (Table 1). The remaining vehicle ingredients (monoglycerides and triglycerides) were not available for testing but have not been previously reported to cause ACD. Therefore, we suspect she had developed contact allergy to the active ingredient crisaborole. The clinical relevance of this patient's crisaborole reaction is unclear. However, this case further demonstrates that crisaborole can cause contact allergy. Kimyon and colleagues have previously reported two patients who developed ACD to crisaborole.5 Clinicians should be aware of the allergenic potential of this substance when treating atopic dermatitis. Puneet Arora: Conceptualization; investigation; writing – original draft; writing – review and editing; project administration; data curation; methodology; software; visualization. Anne Neeley: Conceptualization; investigation; writing – review and editing; methodology; validation; supervision; data curation; resources; writing – original draft. The authors declare no conflicts of interest.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Park Nicollet Health Services, Minneapolis, Minnesota, USA.
- University of Minnesota Medical School, Minneapolis, Minnesota, USA.
ORCID profiles: Puneet Arora
Cite
APA
Arora, P., & Neeley, A. (2023). Contact allergy to crisaborole in a paediatric patient with atopic dermatitis. Contact Dermatitis. https://doi.org/10.1111/cod.14389
Vancouver
Arora P, Neeley A. Contact allergy to crisaborole in a paediatric patient with atopic dermatitis. Contact Dermatitis. 2023. doi:10.1111/cod.14389
BibTeX
@article{Arora2023,
author = {Arora, Puneet and Neeley, Anne},
title = {Contact allergy to crisaborole in a paediatric patient with atopic dermatitis},
journal = {Contact Dermatitis},
year = {2023},
doi = {10.1111/cod.14389}
}
EUVIMED